Purdue University

Purdue e-Pubs
Department of Comparative Pathobiology Faculty
Publications

Department of Comparative Pathobiology

9-25-2012

The effect of infection order of porcine circovirus
type 2 and porcine reproductive and respiratory
syndrome virus on dually infected swine alveolar
macrophages
Yi-Chieh Tsai
Hui-Wen Chang
Chian-Ren Jeng
Tsang L. Lin
Purdue University, tllin@purdue.edu

Chun-Ming Lin
See next page for additional authors

Follow this and additional works at: https://docs.lib.purdue.edu/cpbpubs
Part of the Veterinary Pathology and Pathobiology Commons
Recommended Citation
This is the publisher pdf of "The effect of infection order of porcine circovirus type 2 and porcine reproductive and respiratory
syndrome virus on dually infected swine alveolar macrophages Yi-Chieh Tsai, Hui-Wen Chang, Chian-Ren Jeng, Tsang-Long Lin,
Chun-Ming Lin, Cho-Hua Wan, Victor Pang BMC Veterinary Research 2012, 8:174 (25 September 2012) " and is available at:
http://www.biomedcentral.com/1746-6148/8/174

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.

Authors

Yi-Chieh Tsai, Hui-Wen Chang, Chian-Ren Jeng, Tsang L. Lin, Chun-Ming Lin, Cho-Hua Wan, and Victor
Fei Pang

This article is available at Purdue e-Pubs: https://docs.lib.purdue.edu/cpbpubs/5

Tsai et al. BMC Veterinary Research 2012, 8:174
http://www.biomedcentral.com/1746-6148/8/174

RESEARCH ARTICLE

Open Access

The effect of infection order of porcine circovirus
type 2 and porcine reproductive and respiratory
syndrome virus on dually infected swine alveolar
macrophages
Yi-Chieh Tsai1†, Hui-Wen Chang1†, Chian-Ren Jeng1,2, Tsang-Long Lin3, Chun-Ming Lin1, Cho-Hua Wan1,2*
and Victor Fei Pang1,2*

Abstract
Background: Concurrent infection with porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory
syndrome virus (PRRSV) is known as one of the major causes for porcine respiratory disease complex (PRDC). Dual
infection with PCV2 and PRRSV is consistently to have more severe clinical presentations and pulmonary lesions
than infection with PCV2 alone or PRRSV alone. However, it is not known if dual infections with PCV2 and PRRSV in
different infection order may lead to different clinical symptoms in the host. To mimic the possible field conditions,
swine alveolar macrophages (AMs) were inoculated with PCV2 and PRRSV in vitro simultaneously or with one virus
18 h earlier than the other. The cell viability, cytopathic effects, antigen-containing rates, phagocytotic and microbial
killing capabilities, cytokine profiles (IL-8, TNF-α, and IFN-α) and FasL transcripts were determined, analyzed, and
compared to prove the hypothesis.
Results: A marked reduction in PRRSV antigen-containing rate, cytopathic effect, and TNF-α expression level was
revealed in AMs inoculated with PCV2 and PRRSV simultaneously and in AMs inoculated with PCV2 first then PRRSV
18 h later, but not in AMs inoculated with PRRSV first then PCV2 18 h later. Transient decrease in phagocytosis but
constant reduction in microbicidal capability in AMs in the group inoculated with PCV2 alone and constant
decrease in phagocytosis and microbicidal capability in AMs in all PRRSV-inoculated groups were noted. The levels
of IL-8, TNF-α, IFN-α, and FasL transcripts in AMs in all groups with dual inoculation of PCV2 and PRRSV were
significantly increased regardless of the infection orders as compared with infection by PCV2 alone or PRRSV alone.
Conclusions: Swine AMs infected with PCV2 first then PRRSV later or infected with PCV2 and PRRSV simultaneously
displayed marked reduction in PRRSV antigen-containing rate, cytopathic effect, and TNF-α expression level. The
different inoculation orders of PCV2 and PRRSV in AMs leading to different results in viral antigen positivity,
cytopathology, and cytokine profile may explain, at least partially, the underlying mechanism of the enhanced
pulmonary lesions in PRDC exerted by dual infection with PCV2 and PRRSV and the variable clinical manifestations
of PRDC-affected pigs in the field.
Keywords: Porcine circovirus type 2, Porcine reproductive and respiratory syndrome virus, Alveolar macrophages,
Porcine respiratory disease complex
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Background
Porcine respiratory disease complex (PRDC) is one of
the major problems to the swine industry worldwide and
arguably the most important swine health concern for
the swine producers today. During the past 30 years,
swine production has been intensified with larger herd
sizes and confinement rearing, contributing to the
increased incidence and complexity of the respiratory
diseases. Porcine respiratory disease complex often
occurs in pigs around 6 to 20 weeks of age, especially in
large pig farms with continuous production system [1].
It is characterized clinically by slow growth, decreased
feed efficiency, anorexia, lethargy, fever, cough, and difficult breathing [1,2]. A multifactorial complex of swine
respiratory pathogens has been reported to play a role or
roles in PRDC, including bacteria and viruses, which are
complicated by management and environmental factors
[1,3]. However, the pathogens involved vary significantly
among farms and production sites. The viral agents that
have been isolated from PRDC are porcine reproductive
and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), swine influenza virus (SIV),
pseudorabies virus (PRV), porcine respiratory coronavirus (PRCV), and recently Torque Teno viruses (TTV)
[1-7]. The bacterial pathogens involved in PRDC include
Mycoplasma hyopneumoniae, Pasteurella multocida,
Actinobacillus pleuropneumonia, Streptococcus suis,
Haemophilus parasuis, and Salmonella enterica serotype
Chloeraesuis [1,3,7]. Procine circovirus type 2, PRRSV, P.
multocida, and M. hyopneumoniae are the most important PRDC-inducing viral and bacterial pathogens, respectively, in Taiwanese swine industry [7].
Porcine circovirus type 2 and PRRSV have been suggested to be two of the important etiological factors for
PRDC, and pigs with dual infections of PCV2 and
PRRSV, however, consistently have more severe clinical
symptoms and interstitial pneumonia [3,4,8-10]. Swine
alveolar macrophages (AMs) co-inoculated with PCV2
and PRRSV have been shown to have significantly higher
expression levels of Fas ligand and Fas than those inoculated with PRRSV alone [11]. In addition, co-infection of
PCV2 and PRRSV in piglets synergistically has been
found to suppress the mRNA expression profiles of T
helper (Th) 1- and Th2-type cytokines in the peripheral
blood mononuclear cells (PBMCs) [12]. Furthermore,
dual infection of PCV2 and PRRSV in pigs with a PCV2
mutant that has the mutation at the interferonstimulated response element (ISRE)-like element could
exacerbate the pathological lesions and increase the
PCV2 viral DNA load in the tissues [13]. These findings
indicate that the interactions of PCV2 and PRRSV are
critical to the pathogenesis of PRDC.
Pulmonary alveolar and/or intravascular macrophages
are known as the major target cells for both PCV2 and
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PRRSV in the lungs [14-17]. We have previously used
in vitro approaches to study the effect of infection with
PCV2 alone [15] or PRRSV alone [18] on the functional
changes of swine AMs; it was found that either PCV2
alone or PRRSV alone could cause significant reduction
in the microbicidal capability and induce changes in expression levels of cytokine and chemokine, which may
explain partially the pathologic changes in the infected
pig lungs. In a co-infection study with PCV2 and
PRRSV, instead of observing an enhanced effect, PCV2
reduced PRRSV replication and PRRSV-associated cytopathy by inducing IFN-α production in swine AMs [14].
Such findings, however, do not reflect and explain the
enhanced clinical disease observed in PRRSV and PCV2
dually infected cases in the field. Therefore, the effects
of dual PCV2 and PRRSV infection on the functions of
swine AMs need further elucidated.
In a pig farm infected with PCV2 and PRRSV, it is
conceivable that individual pigs may be attacked by both
viruses in different sequence or order. The objective of
the present study was to determine if different infection
orders of PCV2 and PRRSV would result in different
consequences in the functions of swine AMs by the
in vitro inoculation of swine AMs with PCV2 and/or
PRRSV.

Methods
Experimental animals and viruses

The animal use and care protocol was reviewed and
approved by the Institutional Animal Care and Use
Committee (IACUC) of National Taiwan University
(NTU). Twelve, 5 to 6 weeks old, specific pathogen free
(SPF) pigs were obtained from the Animal Technology
Institute Taiwan; they were certified to be free of classical swine fever virus, foot and mouth disease virus,
Aujeszky’s disease virus, Toxoplasma gondii, P. multocida, Bordetella bronchiseptica, M. hyopneumoniae, A.
pleuropneumoniae, and Brachyspira hyodysenteriae. The
SPF pigs were also tested negative for PRRSV, PCV1,
and PCV2 antibodies and nucleic acids by immunofluorescent antibody assay (IFA) or real time PCR and used
for the collection of AMs. These pigs were kept in the
isolated laboratory animal facility with air conditioning
system. Animal euthanasia was conducted in accordance
with the Report of the AVMA Panel on Euthanasia and
under the supervision of IACUC of NTU.
The stock of PRRSV used in the study was the 8th
passage of a Taiwan field isolate, PRRSV tw91, at a titer
of 107 TCID50/ml, which was prepared and titrated on
MARC-145 by cytopathic effect (CPE) [18]. The PCV2
used in the study was a field isolate by using pooled
spleen and lymph nodes from a PMWS-affected pig with
a PCV1/PCV2-free PK-15 cell line; the virus was
sequenced as PCV2b subtype and the stock was
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prepared as previously described at a titer of 5 x 106
TCID50/ml [14].
Preparation of AMs

The bronchoalveolar lavage and collection of AMs were performed as described previously [14]. The AMs were adjusted
to 5 x 105 cells/ml in RPMI-1640 medium (Gibco Laboratories, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal bovine serum (FBS) (Hyclone, Laboratories,
Logan, UT) and 1% 100x antibiotic-antimycotic solution
(Gibco), containing 10,000 units of penicillin, 10,000 μg of
streptomycin, and 25 μg of amphotericin B/ml in 0.85% saline, (RPMI-C). Three milliliters/flask or 0.5 ml/well of AMs
were placed in Teflon flasks (Nalgene Company, Rochester,
USA) or 24-well culture plates (Costar, Cambridge, MA,
USA) with or without coverslips (Assistent, Nürtingen,
Germany), respectively, and immediately exposed to one or
both viruses or equal volume of RPMI-C. The flasks and
culture plates were incubated at 37 in 5% CO2 for various
time intervals as indicated below. The AMs were subsequently evaluated for antigen-positive rate, survival rate,
TUNEL-positive rate, phagocytosis, microbial killing capacity, cytokine production, and Fas and FasL mRNA
expression.
Experimental design

Six groups of AMs were used, including AMs inoculated
with PCV2 alone (PCV2), AMs inoculated with PRRSV
alone (PRRSV), AMs inoculated with PCV2 first then
inoculated with PRRSV 18 h later (PCV2/PRRSV), AMs
inoculated with PRRSV first then inoculated with PCV2
18 h later (PRRSV/PCV2), AMs co-inoculated with
PCV2 and PRRSV simultaneously (PCV2-PRRSV), and
AMs inoculated with an equal volume of RPMI-C
(Mock). The multiplicity of infection (m.o.i.) for PCV2
and PRRSV was 0.1 each, respectively. At 18, 36, 54, 72,
90, and 108 h post inoculation (HPI) with the first virus,
AMs or supernatants from all of the treatment groups
were collected and used for assays of antigen-positive
rate, survival rate, TUNEL-positive rate, phagocytosis,
microbial killing capacity, and cytokine production. For
the measurement of mRNA expression of Fas and FasL,
AMs were collected at 42 HPI after the removal of culture supernatant.
Antigen-positive rate

The PCV2 antigens and nucleocapsid protein of PRRSV
were detected by IFA with specific antibodies as
described previously [14]. The rates of positivity were
determined by counting 200 cells out of 10 randomly
selected fields at 400x magnification on a fluorescent
microscope (Optiphoto II, Nikon, Tokyo, Japan).
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Survival rate

The cytocidal effect of PCV2 and/or PRRSV on AMs was
determined using the trypan blue dye exclusion assay
[14]. The numbers of trypan blue-positive and trypan
blue-negative cells were counted on a hemocytometer
by light microscopy as described previously [18]. The
survival rate (SR) was recorded as [(number of trypan
blue-negative cells/total number of trypan blue-positive
and trypan blue-negative cells) x 100%]. Data of SR were
expressed as the level different from that of the Mock:
[(SR value of PCV2- and/or PRRSV-inoculated group) (SR value of Mock group)].
TUNEL-positive rate

The terminal deoxynucleotidyl transferase (TdT)mediated dUTP nick end-labeling (TUNEL) assay was
performed according to the manufacturer’s instructions
(in situ cell death detection kit, fluorescein; Boehringer
Mannheim, Mannheim, Germany) and counterstained
with 1% Hoechst 33258 (Sigma) as described previously
[14]. The percentage of TUNEL-positive cells was determined by counting 200 cells out of 10 randomly selected
fields at 400x on a fluorescent microscope (Optiphoto II,
Nikon). The TUNEL-positive rate (TR) was recorded as
[(number of TUNEL-positive cells/200 Hoechst-positive
cells) x 100%]. Data of TR were expressed as the level
different from that of the Mock: [(TR value of PCV2
and/or PRRSV-inoculated group) - (TR value of Mock
group)].
Phagocytosis and microbial killing assays

The phagocytosis and microbial killing assays were carried out as those described previously [15] by using Candida albicans as the target. Briefly, monolayers of AMs
were incubated with spores of C. albicans, opsonised
with pooled swine hyperimmune serum, in an AMs to
yeast ratio of 1:10 for 60 min. Following PBS wash to remove non-phagocytized yeasts, the monolayers of AMs
were stained with acridine orange (AO) (Sigma) and
counterstained with crystal violet (Sigma). Under a fluorescent microscope (Optiphoto II, Nikon), the dead yeasts
displayed an orange fluorescence and the viable ones had
a green fluorescence. The number of AMs containing 1
or more yeasts in 200 randomly selected viable cells and
among which the number of AMs containing killed
yeasts were counted manually. The phagocytotic rate
(PR) and microbicidal rate (KR) were recorded as [(number of AMs containing 1 or more yeasts in randomly
selected viable cells/total number of viable cells) x 100%]
and [(number of AMs containing killed yeasts in randomly selected viable cells/total number of viable cells) x
100%]. They were further expressed as the level different
from that of the Mock: [(PR value of PCV2- and/or
PRRSV-inoculated group) - (PR value of Mock group)]
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and [(KR value of PCV2- and/or PRRSV-inoculated
group) - (KR value of Mock group)], respectively.
Interleukin 8 (IL-8) and tumor necrosis factor (TNF)-α
titration

The protein levels of IL-8 and TNF-α in the supernatants collected at each time point were determined
using the commercial ELISA kits (Biosource, Camarillo,
California, USA) according to the manufacturer’s instruction. The plates were read on an ELISA reader
(Bio-Tek Instruments, Vermont, USA) at 550 nm. Data
were expressed as mean concentration at pg/ml, where
they were obtained by converting the OD value of each
sample to the corresponding concentration based on the
standard curve obtained from the 10-fold serial dilution
of each recombinant porcine cytokine with known concentration. They were further expressed as the level different from that of the Mock: [(value of PCV2- and/or
PRRSV-inoculated group) - (value of Mock group)].
Interferon (IFN)-α bioassay

The IFN-α bioassay was performed as described previously by using Madin-Darby bovine kidney (MDBK)
cells and vesicular stomatitis virus (VSV) [14]. Recombinant porcine IFN-α (Chemicon, Temecula, California,
USA) was used as a standard. Data were recorded as
mean unit (U)/ml, where 1 U of IFN-α activity was
defined as the reciprocal of the dilution producing 50%
inhibition of cytopathic effect (CPE). They were further
expressed as the level different from that of the Mock:
[(value of PCV2- and/or PRRSV-inoculated group) (value of Mock group)].

Total RNA was extracted from AMs using TRIzol reagent
(Life Technologies, Paisley, Scotland, UK), reversetranscribed to cDNA, and amplified by PCR with the following primers: porcine Fas (sense: 50-GCA GGA TCC
AGA TCT AAT CTA CAC-30, antisense: 50-CTA GGC
AGG TTG TTT AGA GGC AGT-30) [19], porcine FasL
(sense: 50-AAT GGG AAG ACA CCT ATG GAA-30,
antisense: 50-CTT AGA GCT TAT ATA AGC CGA AAA
ACG TC-30) [20], and a porcine internal control GAPDH
(sense: 50-ACC TCC ACT ACA TGG TCT ACA TGT
TC-30, antisense: 50-CAT TGA TGA CAA GCT TCC
CAT TC-30). Amplifications were performed with a thermocycler (MJ Research, Watertown, MA) using 30 cycles
(95°C for 45 s, 62°C for 45 s, 72°C for 1 min) for Fas; 33
cycles (94°C for 40 s, 55°C for 40 s, 72°C for 1 min) and
additional extension at 72°C for 5 min at the end of amplification for FasL; and 40 cycles (95°C for 15 s, 60°C for
1 min, 72°C for 1 min) for GAPDH. The PCR products
were separated on a 2% Tris/Borate/EDTA (TBE) agarose
gel by electrophoresis and stained with ethidium bromide
(Sigma). The gels were photographed and analyzed using
the ChemiDoc™ XRS (Bio-Rad, Segrate, Milan, Italy). The
intensity of Fas or FasL was normalized to that of the
GAPDH. Data were expressed as the level different from
that of the Mock: [(value of PCV2- and/or PRRSVinoculated group) - (value of Mock group)].
Statistical analysis

The means presented in figures and used in statistical
analyses represent at least three independent trials per

(B)
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PCV2/PRRSV
PCV2-PRRSV
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PRRSV antigen-positive rate (%)

PCV2 antigen-positive rate (%)
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Semiquantitative analysis of Fas and FasL transcripts by
RT-PCR
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Figure 1 Changes in PCV2 and PRRSV antigen-positive rate in swine alveolar macrophages (AMs). Changes in (A) PCV2 and (B) PRRSV
antigen-positive rate in PCV2- and/or PRRSV-inoculated swine alveolar macrophages (AMs) were determined by indirect immunofluorescence
assay. Data are expressed as percentage and shown as mean ± SD of three independent experiments. Solid diamond: inoculation with PCV2
alone (PCV2); open diamond: inoculation with PRRSV alone (PRRSV); solid square: inoculation with PCV2 and PRRSV simultaneously (PCV2-PRRSV);
solid triangle: inoculation with PCV2 for 18 h first then PRRSV later (PCV2/PRRSV); open triangle: inoculation with PRRSV for 18 h first then PCV2
later (PRRSV/PCV2). *** (P < 0.001) The values are significantly different from PRRSV or PRRSV/PCV2 at the same h post PRRSV inoculation.
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main experiment run concurrently. The effects of the
different treatments on antigen-positive rate, survival
rate, TUNEL-positive rate, phagocytotic and microbial
killing capabilities were analyzed by generalized linear
models with the use of PROC GENMOD and binomial
statement in Statistical Analysis System (Statistical Analysis System; SAS for windows 6.12; SAS Institute Inc.,
Cary, NC, USA). The P values were then adjusted by
using Bonferroni test in the MULTTEST procedure in
SAS. The data of cytokine expression levels and levels of
Fas/FasL transcripts were analyzed by analysis of variance (ANOVA) followed by Duncan's multiple-range test
carried out by SAS procedures. A P value of less than
0.05 was considered significant.

each other at any time points. The SRs of AMs in the
PCV2/PRRSV groups were 80.1 ± 4.9% at 18 HPI and
slightly reduced from 76.3 ± 4.5% to 68.3 ± 5.7% after
PRRSV inoculation during 36 to 108 HPI with no significant differences from those of the Mock group. However,
they were significantly lower (P < 0.001) than those of the
PCV2 group at 36 HPI, but significantly higher (P < 0.02)
than those of the PRRSV and PRRSV/PCV2 groups at 18
HPI, 72 to 108 HPI and during 72 to 108 HPI, respectively. In PCV2-PRRSV group, the SRs of AMs were
55.6 ± 12.1% to 64.0 ± 14.0% during the experimental
period and were significantly higher (P < 0.001) than those
of the PRRSV and PRRSV/PCV2 groups at 108 HPI
(Figure 2A).

Results

TUNEL-positive rate of PCV2- and/or PRRSV-inoculated
swine AMs

Antigen-positive rate of PCV2- and/or PRRSV-inoculated
swine AMs

During 18 to 108 HPI, a steady positive rate of pin-like
intracytoplasmic signals for PCV2 antigens, ranging from
91.7 ± 2.3 to 96.3 ± 0.5%, was detected in all groups receiving PCV2 (Figure 1A); a low but constant intracytoplasmic
PRRSV antigen-positive rate, about 5.2 ± 1.0 to 9.9 ± 0.2%
and 6.1 ± 0.5 to 9.1 ± 1.3%, was noted in the groups of
PRRSV and PRRSV/PCV2, respectively (Figure 1B). No
intranuclear PCV2 or PRRSV antigens were observed during the experimental period. In the groups of PCV2/
PRRSV and PCV2-PRRSV, however, the PRRSV antigenpositive rates were 5.6 ± 1.1% and 4.2 ± 0.1% at 36 HPI, but
it gradually reduced to 1.2 ± 0.2 % and 3.5 ± 0.4% at 72
HPI, then further dropped to 0.9 ± 0.3% and 2.9 ± 1.1% by
108 HPI, respectively. They were constantly and significantly lower (P < 0.041) than those of PRRSV and PRRSV/
PCV2 groups during 54 to 108 HPI (Figure 1B). Neither
PCV2 nor PRRSV antigens were detected in AMs from the
pigs in the Mock group.
Survival rate of PCV2- and/or PRRSV-inoculated swine
AMs

Before virus inoculation, the SR of AMs was 97.5 ± 0.7%.
During 18 to 108 HPI, it became 80.1 ± 1.9 to 83.7 ± 1.5%
and 88.8 ± 0.9 to 93.5 ± 2.5% in the Mock and PCV2 groups,
respectively. The SRs of AMs in the PCV2 group were
8.1 ± 6.0% to 11.7 ± 0.7% higher than those of the Mock
group, however, the differences were not statistically significant (P > 0.269). On the contrary, the SRs of all PRRSVinoculated groups, except for the PCV2/PRRSV group,
decreased after PRRSV inoculation and were significantly
lower (P < 0.001) than those of the Mock and PCV2 groups
throughout the experimental period. The SRs reduced in a
time-dependent manner in the PRRSV and PRRSV/PCV2
groups; they were 66.0 ± 3.4% and 66.8 ± 1.3% at 18 HPI
and dropped to 35.1 ± 3.2% and 27.0 ± 16.5% at 108 HPI, respectively, with no significant difference (P > 0.275) between

The TRs of AMs were very low in both Mock and PCV2
groups throughout the experimental period. They were
1.4 ± 0.3% to 2.7 ± 0.1% for the Mock group and 1.4 ± 0.3
to 2.3 ± 0.8% for the PCV2 group. However, a significant
increase (P < 0.037) in TRs was seen after the addition of
PRRSV in all PRRSV-inoculated groups as compared
with those of the Mock and PCV2 groups. The TRs of
AMs in the PRRSV and PRRSV/PCV2 groups were
21.8 ± 1.1% to 33.9 ± 0.7% and 25.0 ± 1.0 to 28.6 ± 5.5%,
respectively; they were consistently higher than those of
the Mock group but there were no significant differences
(P > 0.133) between the two groups during the experimental period. The TRs of AMs in the PCV2/PRRSV
group increased to 18.1 ± 6.9% at 36 HPI after PRRSV
inoculation, but they gradually reduced to 6.8 ± 3.1% by
108 HPI. The TRs of AMs in the PCV2-PRRSV group
were 17.8 ± 2.5% at 18 HPI, raised to 26.7 ± 3.1% at 36
HPI, then gradually reduced to 12.3 ± 1.7% by 108 HPI.
They were significantly lower (P < 0.001) than those of
the PRRSV and PRRSV/PCV2 groups at 90 to 108 HPI
(Figure 2B).
Phagocytosis and microbicidal capacity of PCV2- and/or
PRRSV-inoculated swine AMs

As far as the phagocytosis rate (PR) was concerned
(Figure 3A), 88.1 ± 0.6 to 91.0 ± 5.5% of AMs in the
Mock group were able to engulf one or more C. albicans
during 18 to 108 HPI. The PRs of AMs in the PCV2
group were constantly lower than those of the Mock
group with differences ranging from 2.2 ± 5.5% to
14.4 ± 0.6% throughout the experimental period and
were significantly different from those of the Mock
group during 18–36 HPI (P < 0.001). The PRs of AMs
from all PRRSV-inoculated groups were consistently and
significantly lower (P < 0.026) than those of the Mock
and PCV2 groups after PRRSV inoculation during 36–
108 HPI. As for the PRs of AMs in the PCV2/PRRSV
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Figure 2 Changes in survival rate and apoptotic rate of swine alveolar macrophages (AMs). Changes in (A) survival rate and (B) apoptotic
rate in PCV2- and/or PRRSV-inoculated swine alveolar macrophages (AMs) were determined by trypan blue dye exclusion assay and TUNEL assay,
respectively. Data are expressed as the level different from that of the mock-inoculated AMs (Mock) and shown as mean ± SD of three
independent experiments. PCV2: AMs inoculated with PCV2 alone; PRRSV: AMs inoculated with PRRSV alone; PCV2/PRRSV: AMs inoculated with
PCV2 first then inoculated with PRRSV 18 h later; PRRSV/PCV2: AMs inoculated with PRRSV first then inoculated with PCV2 18 h later; PCV2-PRRSV:
AMs co-inoculated with PCV2 and PRRSV simultaneously. ** (P < 0.01), *** (P < 0.001)The difference between the two treatment groups at the same h
post inoculation (HPI) with the first virus is statistically significant. aValues are significantly different from the Mock at the same h post inoculation
(HPI) with the first virus.

and PCV2-PRRSV groups, the average PRs were similar
between the two groups throughout the study but they
were significantly higher (P < 0.015) than those of the
PRRSV group during 90 to 108 HPI.
With regard to the microbicidal capacity (KR)
(Figure 3B), 73.3 ± 10.5 to 76.2 ± 5.9% of AMs in the
Mock group engulfed one or more C. albicans during
the experimental period. The KRs of AMs from all
PCV2- and/or PRRSV-inoculated groups (except for the
PCV2 group at 18 HPI) were consistently and significantly lower (P < 0.001) than those of the Mock group
during the experimental period with differences ranging

from 26.4 ± 10.1% to 55.9 ± 5.7%. No statistical differences (P > 0.137) in the KRs of AMs were seen among
all PRRSV-inoculated groups although there was a relatively lower KR in the PRRSV/PCV2 group than in the
PCV2/PRRSV, PCV2-PRRSV, and PRRSV groups.
Interleukin 8 (IL-8), tumor necrosis factor (TNF)-α, and
interferon (IFN)-α levels in the supernatants of PCV2- and/
or PRRSV-inoculated swine AMs

The levels of IL-8 (Figure 4A) in all PCV2- and/or PRRSVinoculated groups were 1390.0 ± 49.4 to 2035.5 ± 72.4 pg/ml
and were all significantly higher (P < 0.001) than those
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Figure 3 Changes in phagocytotic and microbial killing capabilities of swine alveolar macrophages (AMs). Changes in (A) phagocytotic
and (B) microbial killing capabilities in PCV2- and/or PRRSV-inoculated swine alveolar macrophages (AMs) were determined by using Candida
albicans as the target. Following 60 min of incubation and staining with acridine orange, the percentages of viable AMs with engulfed yeasts and
killed yeasts were determined. Data are expressed as the level different from that of the mock-inoculated AMs (Mock) and shown as mean ± SD
of three independent experiments. PCV2: AMs inoculated with PCV2 alone; PRRSV: AMs inoculated with PRRSV alone; PCV2/PRRSV: AMs inoculated
with PCV2 first then inoculated with PRRSV 18 h later; PRRSV/PCV2: AMs inoculated with PRRSV first then inoculated with PCV2 18 h later;
PCV2-PRRSV: AMs co-inoculated with PCV2 and PRRSV simultaneously. * (P < 0.05), ** (P < 0.01), *** (P < 0.001)The difference between the two
treatment groups at the same h post inoculation (HPI) with the first virus is statistically significant. aValues are significantly different from the
Mock at the same h post inoculation (HPI) with the first virus.

(ranging from 299.2 ± 8.3 to 931.5 ± 21.3 pg/ml) in the
Mock group. No statistically significant differences
(P > 0.157) in the IL-8 levels in the supernatants of AMs
were seen among all PCV2- and/or PRRSV-inoculated
groups.
The levels of TNF-α (Figure 4B) were low in the
supernatant of AMs in the Mock group during the experimental period. They ranged from 22.4 ± 5.5 to
55.1 ± 8.2 pg/ml. All PCV2- and/or PRRSV-inoculated
groups showed a consistent and significant increase
(P < 0.001) in the production of TNF-α in the

supernatants of AMs than that in the Mock group during 18 to108 HPI. The levels of TNF-α in the supernatants of AMs in the PCV2 group were 188.8 ± 9.3 to
297.7 ± 5.3 pg/ml and were significantly lower (P < 0.028)
than those in all PRRSV-inoculated groups throughout
the experimental period. The levels of TNF-α in the
supernatants of AMs in the PRRSV and PRRSV/PCV2
groups were 494.2 ± 25.1 to 878.4 ± 33.3 pg/ml and
832.4 ± 21.9 to 1149.2 ± 125.1 pg/ml, respectively, and
were about fifteen- to twenty-fold higher than those of
the Mock group. In the PCV2/PRRSV group, the levels
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Figure 4 Changes in the levels of IL-8, TNF-α, and IFN-α production in the supernatants of swine alveolar macrophages (AMs). Changes
in the levels of IL-8 (A), TNF-α (B), and IFN-α (C) produced in PCV2- and/or PRRSV-inoculated swine alveolar macrophages (AMs) were expressed
as the level different from that of mock-inoculated AMs (Mock) and shown as mean ± SD of three independent experiments. PCV2: AMs
inoculated with PCV2 alone; PRRSV: AMs inoculated with PRRSV alone; PCV2/PRRSV: AMs inoculated with PCV2 first then inoculated with PRRSV
18 h later; PRRSV/PCV2: AMs inoculated with PRRSV first then inoculated with PCV2 18 h later; PCV2-PRRSV: AMs co-inoculated with PCV2 and
PRRSV simultaneously. *Significantly different (P < 0.05) from the Mock at the same h post inoculation (HPI) with the first virus. a, b, c, d, eValues
with different labels at the same HPI differ significantly (P < 0.05).

of TNF-α in the supernatants of AMs were 446.9 ± 26.9 to
762.4 ± 20.1 pg/ml, which were significantly lower
(P < 0.014) than those of the PRRSV group at 18 HPI and
during 54 to 108 HPI, significantly lower (P < 0.003) than
those of the PRRSV/PCV2 group during 18 to 108 HPI,
and significantly lower (P < 0.012) than those of the
PCV2-PRRSV group at 18, 54, and 90 HPI, respectively.
The levels of TNF-α in the supernatants of AMs in the
PCV2-PRRSV group were 253.9 ± 47.8 to 459.5 ± 27.9 pg/
ml and significantly lower (P < 0.023)than those of the
PRRSV group during 54 to 108 HPI and the PRRSV/
PCV2 group during 18 to 108 HPI.
The levels of IFN-α bioactivity (Figure 4C) in the
supernatants of AMs in the Mock and PRRSV groups
were low throughout the experimental period. They

ranged from 0 to 69.5 ± 21.5 U/ml and 75.6 ± 65.5 to
125.0 ± 20.3 U/ml, respectively. On the contrary, the
levels of IFN-α in the supernatants of AMs increased
from 1125.0 ± 425.7 to 4815.4 ± 221.5 U/ml in all PCV2inoculated groups and were consistently and significantly
higher (P < 0.001) than those of the Mock and PRRSV
groups.
Fas and FasL transcripts in PCV2- and/or PRRSVinoculated swine AMs

After inoculation of AMs with one or both viruses or
equal volume of RPMI-C at 42 HPI, the mRNA levels of
Fas and FasL were evaluated. Neither AMs from the
Mock group nor AMs from any PCV2- and/or PRRSVinoculated groups expressed detectable level of Fas
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mRNA (data not shown); however, variable FasL mRNA
levels were seen in all PCV2- and/or PRRSV-inoculated
groups (Figure 5A, B). A significant increase (P < 0.001)
in the FasL transcripts was demonstrated in AMs from
all PCV2-inoculated groups as compared with that of
the Mock group. All of the dually inoculated groups displayed a significant enhancement (P < 0.014) in the expression levels of FasL mRNA in AMs as compared with
that of single virus inoculation. Among the PCV2 and
PRRSV dually inoculated groups, the expression levels of
FasL mRNA in AMs from the PCV2-PRRSV group was
significantly higher (P < 0.016) than those of the PCV2/
PRRSV and PRRSV/PCV2 groups.

Discussion
A high prevalence of PCV2 and PRRSV co-infection is
frequently observed in PRDC-affected pigs in many pig
producing countries, including Taiwan [3,10,21,22]. The
present study was conducted to study co-infection of
PCV2 and PRRSV in swine AMs in the pathogenesis of
PRDC by mimicking possible infection conditions/
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Figure 5 Expression levels of FasL mRNA in PCV2- and/or
PRRSV-inoculated swine alveolar macrophages (AMs). The
expression levels of FasL mRNA in all cultures were analyzed at 42 h
after inoculation with the first virus by RT-PCR and electrophoresis.
The sizes of FasL and GAPDH housekeeping gene are 366 and 96 b.
p., respectively (A); values are further normalized using the
housekeeping gene GAPDH and expressed as the relative intensity
at the level different from that of mock-inoculated AMs (Mock) and
shown as mean ± SD of three independent experiments (B). Mock:
AMs inoculated with an equal volume of RPMI-C; PCV2: AMs
inoculated with PCV2 alone; PRRSV: AMs inoculated with PRRSV
alone; PCV2/PRRSV: AMs inoculated with PCV2 first then inoculated
with PRRSV 18 h later; PRRSV/PCV2: AMs inoculated with PRRSV first
then inoculated with PCV2 18 h later; PCV2-PRRSV: AMs
co-inoculated with PCV2 and PRRSV simultaneously. *Significantly
different (P < 0.05) from the Mock. a, b, cValues with different labels
differ significantly (P < 0.05).

situations in the field [23,24]. Similar to our previous
study [14], PCV2 was easily internalized in the cytoplasm of AMs but caused no noticeable cell death; and
PRRSV displayed a low infectious rate but severe cytopathic effect and strong TNF-α induction in AMs.
PCV2-induced IFN-α likely caused reduction in PRRSV
infectious rate and PRRSV-related AMs dysfunction
when AMs were co-inoculated with PCV2 and PRRSV
simultaneously [14,18]. Similar PCV2-induced IFN-α
effects were seen in the PCV2/PRRSV group but not in
the PRRSV/PCV2 group, despite that a significant
amount of IFN-α was also induced in PRRSV/PCV2
group, indicating that the pre-existing or co-existing
PCV2 could interfere or hinder, at least partially, PRRSV
infection. Our previous [14,18] and present studies have
demonstrated that a significant amount of PRRSV antigens and PRRSV-induced cell death and dysfunctions in
AMs could be detected within the first 18 HPI when inoculation of AMs with PRRSV. Those findings indicate
that PRRSV replication and PRRSV-induced dysfunction
and cytokine production in AMs should have occurred
during the first 18 HPI after inoculation of AMs with
PRRSV. Thus, it is reasonable to suggest that as long as
PRRSV has established its infection in AMs prior to
PCV2 inoculation or infection, the subsequent IFN-α
production induced by infection with PCV2 later is incapable of curtailing those adverse effects caused by previous or pre-existing PRRSV infection.
In the study reported by Buddaert et al. [25], pigs
infected with porcine respiratory coronavirus virus
(PRCV) 2 days prior to infection with PRRSV showed a
reduction in PRRSV titer but had no change in PRCVinduced IFN-α production. Similarly, no interference
with PCV2-induced IFN-α production was seen in all
groups with dual infection of PCV2 and PRRSV in the
present study. On the contrary, the study of Albina et al.
[26] showed that swine AMs pre-infected with PRRSV 6
h prior to the inoculation of swine transmissible gastroenteritis virus (TGEV) in vitro resulted in a complete inhibition in TGEV-induced IFN-α production. The above
mentioned results indicate that the interactions among
different viruses are complicated and may lead to different disease courses in the field.
Simultaneous infection of PCV2 and PRRSV is frequently encountered in pig herds worldwide [10,27].
Various field and in vivo and in vitro experimental
studies have been conducted to evaluate the effects of
co-infection of PCV2 and PRRSV [9,10,12-14,27,28].
Simultaneous inoculation with PRRSV and PCV2 viruses
[9,10], or PRRSV inoculated one week prior to PCV2
[28], was commonly used in those in vivo studies.
Results from these field and experimental studies have
demonstrated that PRRSV could cause enhanced PCV2
replication evidenced by higher serum and tissue PCV2
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loads, increased severity of the pathological changes and
clinical manifestation of PCVAD, and higher incidence
of PCVAD [9,10,27,28]. Our previous study has demonstrated that PCV2 cannot efficiently replicate in AMs
unless being activated such as by lipopolysaccharide
in vitro [29], and this may explain why, in contrast to
the above mentioned in vivo studies, no significant
changes in PCV2 antigen-positive rate were seen in the
present study. Owing to that no in vivo study with
PCV2 inoculation first followed by PRRSV has been
reported, it would be of interest to see whether those
alterations seen in PCV2/PRRSV group in the present
study can be reproduced in vivo.
Similar to the findings of our previous studies [15,18],
transient decrease in phagocytosis but persistent reduction in microbicidal capability in the group inoculated
with PCV2 alone and constant decrease in phagocytosis
and microbicidal capability in all PRRSV-inoculated
groups were noted in the present study. The significantly
higher PRs of AMs in the PCV2/PRRSV and PCV2PRRSV groups than those in the PRRSV group during 90
to 108 HPI indicate that PCV2 that was inoculated first
or simultaneously not only hinder PRRSV replication
but also reduce the PRRSV-induced adverse effects on
the phagocytosis of swine AMs. Although with some
variations, the constant and significant reduction in the
capability of swine AMs to kill C. albicans in all PCV2and/or PRRSV-inoculated groups suggests that PCV2
and/or PRRSV infection may lead to the survival and
proliferation of the opportunistic or secondary pathogens and lesion development in pig lungs. This is in
agreement with the findings in PRDC-affected pigs in
the field [4,30]. As suggested by the previous studies
[15,18], the impaired microbicidal capability in PCV2and/or PRRSV-inoculated groups may be partially due to
the reduction in reactive oxygen species production of
swine AMs.
PCV2 can be further subdivided into two main subtypes, PCV2a and PCV2b [31]. Although PCV2a has
been considered as less virulent compared to PCV2b
based on field observation [32], no experimental studies
have been able to support this speculation by using
PCV2 infection alone [33] or PCV2 and PRRSV coinfection [34]. Our preliminary study with PCV2a also
showed no difference from PCV2b on the reduction of
the phagocytotic and microbial killing capabilities of
AMs in vitro (unpublished data).
Fas (CD95)/Fas ligand (FasL) has been shown to play a
major role in the induction of apoptosis in immune cells
and bronchial epithelial cells [35-37] and mediation of
neutrophil chemotaxis [38-40]. The ability of FasL to induce acute inflammatory response is even stronger than
that of bacterial lipopolysaccharide (LPS) [41]. The FasL
expressed by AMs has also been suggested to participate
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in the pathogenesis of acute respiratory disease syndrome
(ARDS) [41]. To further elucidate the possible mechanism
of pulmonary inflammatory response and tissue injury
during PCV2 and/or PRRSV infection, Fas and FasL
expressions were also analyzed in the present study. The
results of FasL mRNA expression clearly showed that
PCV2 but not PRRSV could stimulate swine AMs to produce FasL; however, PRRSV had the addictive effect on
PCV2-related FasL mRNA expression in swine AMs when
PRRSV co-existed with PCV2. Comparing with PCV2/
PRRSV or PRRSV/PCV2 group, a significantly higher level
of FasL mRNA expression was seen in the PCV2-PRRSV
group. At 42 HPI, the duration for co-existence of PCV2
and PRRSV in the PCV2/PRRSV or PRRSV/PCV2 group
was 18 h less than that in the PCV2-PRRSVgroup. The result suggests that the addictive effect of PRRSV on the enhancement of FasL mRNA expression by PCV2
corresponds with the duration for co-existence and interaction of PCV2 and PRRSV. A significant increase in FasL
mRNA expression with no detectable Fas mRNA expression in all PCV2- and/or PRRSV- inoculated AMs suggests that Fas/FasL may not be directly involved in the
apoptosis and other cytopathologies in the PCV2- and/or
PRRSV-inoculated AMs.
Pigs naturally infected with PCV2 and/or PRRSV frequently show interstitial pneumonia [10,42]. Inoculation
of PCV2 or PRRSV alone has been shown to cause mild
to moderate interstitial pneumonia in conventional pigs;
however, severe interstitial pneumonia with occasional
peribronchiolar mononuclear cell cuffing and scattered
individual bronchiolar epithelial cellular necrosis could
be induced in Cesarean-derived colostrum-deprived pigs
with dual infection of PCV2 and PRRSV [9,30].
Interferon-α activation in cellular immunity has been
suggested to complicate interstitial pneumonia [37].
Tumor necrosis factor-α can induce strong proinflammatory response, including the release of inflammatory
mediators and chemokines [43]. Interleukin 8 is an acute
inflammatory chemokine for neutrophils and also considered as a key factor in the pathogenesis of interstitial
pneumonia [44]. In addition, FasL has been suggested to
be associated with the process of pulmonary inflammation and vascular permeability and the induction of epithelial apoptosis when it ligates with the airway
epithelial cells expressing Fas [39,41]. Taken together,
the increased expression of IFN-α, TNF-α, IL-8, and
FasL mRNA in AMs from pigs in various infection
orders by PCV2 and PRRSV observed in the present
study, to some extent may contribute to pneumonia and
bronchiolar epithelial damage in the lungs of PCV2and/or PRRSV-infected pigs.
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